🏛️ Verified NIH Record • Updated 2026-01-23

Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC (NCT04958811)

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Georgetown University

🩺 Plain-English Summary (8th-Grade Level)

To evaluate the efficacy of tiragolumab with atezolizumab and bevacizumab in previously-treated advanced non-squamous NSCLC.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (31 items) and avoid the listed exclusions (36 items).

Location: MedStar Georgetown University Hospital — Washington D.C., District of Columbia

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Usually NOT eligible if any of the following apply:

  • Exclusion Criteria:
  • Prior treatment with anti-TIGIT antibody therapy
  • Prior treatment with anti-PD(L)1 therapeutic antibodies for advanced NSCLC (cohort B only)
  • Untreated or symptomatic CNS metastases
  • History of leptomeningeal disease
  • Active or history of clinically significant autoimmune disease that, in the opinion of the investigator, could compromise the health and safety of the patient if treated with investigational therapy. Notable exceptions include:
  • Patients with a history of autoimmune-related hypothyroidism who are on thyroid-replacement hormone.
  • Patients with controlled Type 1 diabetes mellitus who are on an insulin regimen.
  • Active or history of adrenal insufficiency on stable steroid regimen.
  • Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only are eligible for the study provided all of following conditions are met: disease is well controlled at baseline and requires only low-potency topical corticosteroids; no occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high-potency oral corticosteroids within the previous 12 months
  • History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted.
  • Known active tuberculosis

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (2 Sites)

  • MedStar Georgetown University Hospital — Washington D.C., District of Columbia
  • John Theurer Cancer Center at Hackensack University Medical Center — Hackensack, New Jersey

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
🏛️ View Official NIH Record ↗